Suppr超能文献

miR-34家族的过表达抑制具有野生型p53基因的恶性黑色素瘤的侵袭性生长。

Overexpression of the miR-34 family suppresses invasive growth of malignant melanoma with the wild-type p53 gene.

作者信息

Yamazaki Hitoshi, Chijiwa Tsuyoshi, Inoue Yoshimasa, Abe Yoshiyuki, Suemizu Hiroshi, Kawai Kenji, Wakui Masatoshi, Furukawa Daisuke, Mukai Masaya, Kuwao Sadahito, Saegusa Makoto, Nakamura Masato

机构信息

Department of Pathology, Kitasato University School of Medicine, Kanagawa;

出版信息

Exp Ther Med. 2012 May;3(5):793-796. doi: 10.3892/etm.2012.497. Epub 2012 Feb 28.

Abstract

Malignant melanoma is the most aggressive neoplasm, with severe metastatic potential. microRNAs represent a class of endogenously expressed, small non-coding RNAs that regulate gene expression. As a consequence, the translation of these mRNAs is inhibited or they are destabilized resulting in downregulation of the encoded protein. The microRNA-34 (miR-34) family, which comprises three processed microRNAs (miR-34a/b/c) was identified as the mediator of tumor suppression by p53. Many reports suggest that the miR-34s contribute to the inhibition of invasion or metastasis in various tumor types. In this study, we evaluated the expression of the miR-34 family in four human melanoma cell lines (A375, G361, C32TG and SK-MEL-24) which have the wild-type p53 gene using real-time reverse transcription PCR. We also examined their generative and invasive characteristics using the cell proliferation assay and the invasion/migration assay, respectively. All four melanoma cell lines showed significant expression of miR-34s - A375: miR-34a 0.6176, miR-34b 0.7625, miR-34c 0.7877; G361: 7.6424, 16.4127, 22.0332; C32TG: 2.1630, 2.1091, 8.4425; SK-MEL-24: 0.3621, 2.5659, 8.5907. The cell doubling times of these cell lines in h:min were as follows: A375 23:23, G361 68:24, C32TG 47:22 and SK-MEL-24 67:03. The in vitro generation times of G361 and SK-MEL-24, which showed increased expression of miR-34c, were significantly shorter than A375 with decreased expression of miR-34c (p=0.0063, ANOVA). Invasion (%) of the four cell lines was as follows: A375 44.0%, G361 22.4%, C32TG 13.8% and SK-MEL-24 45.0%. In vitro invasiveness of G361 and C32TG, which showed increased expression of miR-34a, was significantly suppressed (p= 0.005, ANOVA). These results suggest that overexpression of miR-34a and c suppresses invasive and generative potentials, respectively, in human malignant melanoma.

摘要

恶性黑色素瘤是最具侵袭性的肿瘤,具有严重的转移潜能。微小RNA是一类内源性表达的小非编码RNA,可调节基因表达。因此,这些信使核糖核酸的翻译受到抑制或它们变得不稳定,导致编码蛋白的下调。由三种加工后的微小RNA(miR-34a/b/c)组成的微小RNA-34(miR-34)家族被确定为p53介导的肿瘤抑制因子。许多报告表明,miR-34在各种肿瘤类型中有助于抑制侵袭或转移。在本研究中,我们使用实时逆转录聚合酶链反应评估了具有野生型p53基因的四种人类黑色素瘤细胞系(A375、G361、C32TG和SK-MEL-24)中miR-34家族的表达。我们还分别使用细胞增殖试验和侵袭/迁移试验检查了它们的增殖和侵袭特性。所有四种黑色素瘤细胞系均显示出miR-34的显著表达——A375:miR-34a 0.6176,miR-34b 0.7625,miR-34c 0.7877;G361:7.6424,16.4127,22.0332;C32TG:2.1630,2.1091,8.4425;SK-MEL-24:0.3621,2.5659,8.5907。这些细胞系的细胞倍增时间(小时:分钟)如下:A375 23:23,G361 68:24,C32TG 47:22,SK-MEL-24 67:03。miR-34c表达增加的G361和SK-MEL-24的体外增殖时间明显短于miR-34c表达降低的A375(p=0.0063,方差分析)。四种细胞系的侵袭率(%)如下:A375 44.0%,G361 22.4%,C32TG 13.8%,SK-MEL-24 45.0%。miR-34a表达增加的G361和C32TG的体外侵袭性明显受到抑制(p=0.005,方差分析)。这些结果表明,miR-34a和c的过表达分别抑制了人类恶性黑色素瘤的侵袭和增殖潜能。

相似文献

3

引用本文的文献

4
A New Approach to Melanoma Treatment: microRNAs.一种新的黑素瘤治疗方法:microRNAs。
Curr Top Med Chem. 2024;24(16):1362-1376. doi: 10.2174/0115680266291290240417081544.

本文引用的文献

1
Role of miRNAs in the progression of malignant melanoma.微小RNA在恶性黑色素瘤进展中的作用。
Br J Cancer. 2009 Aug 18;101(4):551-6. doi: 10.1038/sj.bjc.6605204. Epub 2009 Jul 28.
5
MicroRNAs impair MET-mediated invasive growth.微小RNA损害MET介导的侵袭性生长。
Cancer Res. 2008 Dec 15;68(24):10128-36. doi: 10.1158/0008-5472.CAN-08-2148.
7
Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.miR-34a对前列腺癌PC3细胞生长和化疗耐药性的影响。
Biochem Biophys Res Commun. 2008 Dec 5;377(1):114-9. doi: 10.1016/j.bbrc.2008.09.086. Epub 2008 Oct 1.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验